达雷木单抗治疗多发性骨髓瘤最新进展研究

The latest progress of daremumab in the treatment of multiple myeloma

多发性骨髓瘤(multiple myeloma,MM)是一种克隆性浆细胞紊乱所致的恶性疾病,表现为贫血、高钙血症、肾功能衰竭和溶骨性病变等。在过去的十年中,随着免疫调节药物(IMiD)和蛋白酶体抑制剂(PI)不断应用,MM的治疗取得了重要的进展,但其死亡率及复发率仍然很高,故仍需探索新的药物及最佳治疗方案。达雷木单抗(daratumumab,DARA)作为一种以CD38为靶点的IgG1κ型全人源单克隆抗体逐渐得到关注和认可,DARA针对不同的患者亚群都获得了显著而持久的疗效,且疗效随着随访时间的延长而趋明显。

Multiple myeloma(multiplemyeloma,MM)is a malignant disease caused by clonal plasma cell disorder,which is characterized by anemia,hypercalcemia,renal failure and osteolytic lesions.In the past decade,with the continuous application of immunomodulatory drug(IMiD)and proteasome inhibitor(PI),important progress has been made in the treatment of MM,but its mortality and recurrence rate are still very high,it is still necessary to explore new drugs and the best treatment.Daremumab(daratumumab,DARA),as an all-human monoclonal antibody targeting CD38,has gradually been paid attention to and recognized.DARA has a significant and lasting effect on different subgroups of patients,and the curative effect becomes obvious with the extension of follow-up time.